Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XC243
- Development stage
- Phase 2
- Lead developer
- Pharmed Enterprises
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
XC243 is an orally bioavailable small molecule antagonist of Toll-like receptor 4 (TLR4) being developed by Pharmenterprises. The drug is designed to treat inflammatory conditions of the bladder, specifically exacerbations of chronic cystitis, by blocking the TLR4-mediated signaling pathways that contribute to inflammation and pain. XC243 has undergone Phase I clinical evaluation for safety and pharmacokinetics in healthy volunteers and has progressed to Phase II multicenter, randomized, double-blind, placebo-controlled trials to assess its efficacy in reducing symptoms such as pain and burning during urination in patients with chronic cystitis.
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on XC243.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XC243.